2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels

Simple item page
dc.contributor.authorYeramian Hakim, Andree
dc.contributor.authorVeà Jódar, Àlvar
dc.contributor.authorBenítez, Sandra
dc.contributor.authorRibera i Calvet, Joan
dc.contributor.authorDomingo, Mónica
dc.contributor.authorSantacana Espasa, Maria
dc.contributor.authorMartínez Alonso, Montserrat
dc.contributor.authorMaiques Carlos, Oscar
dc.contributor.authorValls Marsal, Joan
dc.contributor.authorDolcet Roca, Xavier
dc.contributor.authorVilella, Ramón
dc.contributor.authorCabiscol Català, Elisa
dc.contributor.authorMatias-Guiu, Xavier
dc.contributor.authorMartí Laborda, Rosa Ma.
dc.date.accessioned2017-01-20T11:00:54Z
dc.date.embargoEndDate2025-01-01
dc.date.issued2016
dc.description.abstractHeat shock proteins (HSPs), are molecular chaperones that assist the proper folding of nascent proteins. This study aims to evaluate the antitumour effects of the hsp90 inhibitor NVP-AUY922 in melanoma, both in vitro and in vivo. Our results show that NVP-AUY922 inhibits melanoma cell growth in vitro, with down regulation of multiple signalling pathways involved in melanoma progression such as NF-KB and MAPK/ERK. However, NVP-AUY922 was unable to limit tumour growth in vivo. Cotreatment of A375M xenografts with NVP-AUY922 and PFT-l, a dual inhibitor of both hsp70 and autophagy, induced a synergistic increase of cell death in vitro, and delayed tumour formation in A375M xenografts. PFT-l depleted cells from the reduced form of glutathione (GSH) and increased oxidative stress. The oxidative stress induced by PFT-l further enhanced NVP-AUY922-induced cytotoxic effects. These data suggest a potential therapeutic role for NVP-AUY922 used in combination with PFT-l, in melanoma.ca_ES
dc.description.sponsorshipThis study was suppported by Lliga contra el c ancer de les comarques de Lleida and grants from ISCIII (FIS-PI12/00260 toRMMand RETICSRD12/ 0036/0013 to XMG), from Fundaci o la Marat o de TV3 (FMTV 201331-31 to RMM) and from Generalitat de Catalunya (2014/ SGR138 to XMG) and cofinanced by FEDER ”Una manera de hacer Europa.” Yeramian Andree holds postdoctoral fellowship from AECC. Tumour samples were obtained with the support of Xarxa Catalana de Bancs de Tumours and the Tumour Banc Platform of RTICC (PT13/ 0010/0014). NVP-AUY922 was kindly donated by Novartis. We also thank Dr. Ana€ıs Panosa of the Flow Cytometry Facility at IRBLleida, for her assistance and technical advice.ca_ES
dc.identifier.doihttps://doi.org/10.1111/pcmr.12472
dc.identifier.idgrec024150
dc.identifier.issn1755-1471
dc.identifier.urihttp://hdl.handle.net/10459.1/59060
dc.language.isoengca_ES
dc.publisherWiley online libraryca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1111/pcmr.12472ca_ES
dc.relation.ispartofPigment Cell and Melanoma Research, 2016, vol. 29, núm. 3, p. 352–371ca_ES
dc.rights(c) John Wiley & Sons, 2016ca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccessca_ES
dc.subjecthspca_ES
dc.subjectMelanomaca_ES
dc.subjectGSHca_ES
dc.subjectEndoplasmic reticulumca_ES
dc.subjectPFT-μca_ES
dc.subjectAutophagyca_ES
dc.title2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levelsca_ES
dc.typearticleca_ES
dc.type.versionpublishedVersionca_ES
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Articles publicats (Ciències Mèdiques Bàsiques)
Articles publicats (IRBLleida)
Articles publicats (Medicina Experimental)